These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25152209)

  • 1. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis.
    Joshita S; Umemura T; Ota M; Tanaka E
    J Hepatol; 2014 Dec; 61(6):1443-5. PubMed ID: 25152209
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis".
    Trivedi PJ; Bruns T; Li KK; Hirschfield GM
    J Hepatol; 2014 Dec; 61(6):1445-6. PubMed ID: 25152206
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
    Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
    J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid in primary biliary cirrhosis.
    Combes B
    Semin Liver Dis; 1997 May; 17(2):125-8. PubMed ID: 9170199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary biliary cirrhosis: ursodiol effective, but think transplantation sooner.
    Carithers RL
    Cleve Clin J Med; 1998 Apr; 65(4):174-6. PubMed ID: 9597781
    [No Abstract]   [Full Text] [Related]  

  • 9. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
    Corpechot C; Chazouillères O; Poupon R
    J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment.
    Huet PM; Vincent C; Deslaurier J; Coté J; Matsutami S; Boileau R; Huet-van Kerckvoorde J
    Gastroenterology; 2008 Nov; 135(5):1552-60. PubMed ID: 18722374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransplant ursodeoxycholic acid therapy and liver transplantation in patients with primary biliary cirrhosis: win, win, win?
    Benner KG
    Liver Transpl Surg; 1999 Jul; 5(4):334-7. PubMed ID: 10388507
    [No Abstract]   [Full Text] [Related]  

  • 13. How, why, and when does primary biliary cirrhosis recur after liver transplantation?
    Williams R; Gershwin ME
    Liver Transpl; 2007 Sep; 13(9):1214-6. PubMed ID: 17763403
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary biliary cirrhosis: therapeutic advances.
    Czul F; Peyton A; Levy C
    Clin Liver Dis; 2013 May; 17(2):229-42. PubMed ID: 23540499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The timing of liver transplantation in primary biliary cirrhosis.
    Angulo P; Dickson ER
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):657-68. PubMed ID: 10976021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid for primary biliary cirrhosis.
    Lindor KD; Poupon R; Poupon R; Heathcote EJ; Therneau T
    Lancet; 2000 Feb; 355(9204):657-8. PubMed ID: 10697011
    [No Abstract]   [Full Text] [Related]  

  • 18. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom.
    Corpechot C; Poupon R
    Hepatology; 2007 Oct; 46(4):963-5. PubMed ID: 17894325
    [No Abstract]   [Full Text] [Related]  

  • 19. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
    Lindor K
    N Engl J Med; 2007 Oct; 357(15):1524-9. PubMed ID: 17928600
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Schattenberg JM
    Gut; 2020 Aug; 69(8):1377-1378. PubMed ID: 32205421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.